<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088344</url>
  </required_header>
  <id_info>
    <org_study_id>2013-530, 12-201</org_study_id>
    <nct_id>NCT04088344</nct_id>
  </id_info>
  <brief_title>Effect of a Carbohydrate-rich Diet in Healthy Subjects</brief_title>
  <acronym>AGL9</acronym>
  <official_title>The Relative Contribution of Dietary Lipids vs. of Fatty Acids to Non-adipose Tissues and the Effect of a Carbohydrate-rich Diet in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Université de Sherbrooke</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Université de Sherbrooke</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present research protocol will analyze whether a short-term modification (one week) of
      dietary habits would have an impact on the postprandial metabolism of dietary fatty acids and
      on their uptake by non-adipose tissues, in healthy subjects.

      Each subject will participate in two protocols randomly determined and separated by a period
      of one month: a 7-day isocaloric diet (Protocol A) and a 7-day carbohydrate-rich diet
      containing +50% of the subject's energy needs. (Protocol B).

      At the end of each diet, the subject will go through a postprandial metabolic study of 8
      hours where different parameters will be measured thanks to PET imaging and perfusions of
      stables isotopes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 10, 2013</start_date>
  <completion_date type="Actual">July 2, 2019</completion_date>
  <primary_completion_date type="Actual">March 20, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>whole-body organ-specific Dietary Fatty Acid (DFA) partitioning</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined by whole-body CT (16 mA) followed by PET acquisition of 18FTHA</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Left ventricular function by Positron Emiting Positron (PET) ventriculography</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using 11C-acetate PET/CT. 180 MBq will be administered by bolus injection at fasting. After a transmission scan and regional CT (40mA), a 30-min dynamic list-mode PET acquisition will be performed on a 18 cm-high thoraco-abdominal segment to include the left cardiac ventricle and most of the liver on a Philips Gemini TOF PET/CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac DFA uptake</measure>
    <time_frame>2 months</time_frame>
    <description>will be assessed using PET/CT method with oral administration of 18FTHA followed by a 30 min. dynamic PET acquisition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac and hepatic oxidative metabolism index</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using 11C-acetate PET/CT followed by a 30 minutes dynamic PET acquisition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac and hepatic blood flow</measure>
    <time_frame>2 months</time_frame>
    <description>will be determined using 11C-acetate PET/CT followed by a 30 minutes dynamic PET acquisition..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>metabolites appearance rate</measure>
    <time_frame>6 months</time_frame>
    <description>will be determined by perfusion of stable isotope tracers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>energy metabolism (whole body production)</measure>
    <time_frame>4 months</time_frame>
    <description>by indirect calorimetry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hormonal responses</measure>
    <time_frame>4 months</time_frame>
    <description>analysed by colorimetric and Elisa tests</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin sensitivity</measure>
    <time_frame>4 months</time_frame>
    <description>will be determined using the HOMA-IR (based on fasting insulin and glucose) levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin secretion rate</measure>
    <time_frame>4 months</time_frame>
    <description>will be assessed using deconvolution of plasma C-peptide with standard Cpeptide kinetic parameters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-cell function</measure>
    <time_frame>4 months</time_frame>
    <description>will be assessed by calculation of the disposition index (DI) that is insulin secretion in response to the ambient insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anthropometric parameters</measure>
    <time_frame>2 months</time_frame>
    <description>will be measured at each postprandial metabolic study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Lipid Metabolism Disorder</condition>
  <arm_group>
    <arm_group_label>Isocaloric diet (7 days)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Protocole A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypercaloric diet enriched with carbohydrate food (7 days)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Protocole B</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>isocaloric diet</intervention_name>
    <description>a 7-day isocaloric diet</description>
    <arm_group_label>Isocaloric diet (7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Hypercaloric diet</intervention_name>
    <description>A 7-day hypercaloric diet supplemented with carbohydrate-rich food (+ 50% of the subject's energy needs).</description>
    <arm_group_label>Hypercaloric diet enriched with carbohydrate food (7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Liquid meal</intervention_name>
    <arm_group_label>Hypercaloric diet enriched with carbohydrate food (7 days)</arm_group_label>
    <arm_group_label>Isocaloric diet (7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>PET imaging</intervention_name>
    <arm_group_label>Hypercaloric diet enriched with carbohydrate food (7 days)</arm_group_label>
    <arm_group_label>Isocaloric diet (7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>perfusions of stable tracers</intervention_name>
    <arm_group_label>Hypercaloric diet enriched with carbohydrate food (7 days)</arm_group_label>
    <arm_group_label>Isocaloric diet (7 days)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Indirect calorimetry</intervention_name>
    <arm_group_label>Hypercaloric diet enriched with carbohydrate food (7 days)</arm_group_label>
    <arm_group_label>Isocaloric diet (7 days)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy subjects: subjects with normal glucose tolerance determined according to an oral
        glucose tolerance test and with a BMI above 25 kg/m2 without first degree of familial
        history of type 2 diabetes (parents, siblings).

        Exclusion Criteria:

          -  overt cardiovascular disease as assessed by medical history, physical exam, and
             abnormal ECG

          -  treatment with a fibrate, thiazolidinedione, beta-blocker or other drug known to
             affect lipid or carbohydrate metabolism (except statins, metformin, and other
             antihypertensive agents that can be safely interrupted)

          -  presence of liver or renal disease, uncontrolled thyroid disorder, previous
             pancreatitis, bleeding disorder, or other major illness

          -  smoking (&gt;1 cigarette/day) and/or consumption of &gt;2 alcoholic beverages per day

          -  prior history or current fasting plasma cholesterol level &gt; 7 mmol/l or fasting TG &gt; 5
             mmol/l

          -  any other contraindication to temporarily interrupt current meds for lipids or
             hypertension

          -  being pregnant

          -  not be barren
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Carpentier</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université de Sherbrooke</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre de recherche du CHUS</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 9, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 11, 2019</last_update_submitted>
  <last_update_submitted_qc>September 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Université de Sherbrooke</investigator_affiliation>
    <investigator_full_name>André Carpentier</investigator_full_name>
    <investigator_title>tenured professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Lipid Metabolism Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

